LEOPHARMAUSMEDIA.COM: Keyword Density Checker

Total words: 6797 | 2-word phrases: 1766 | 3-word phrases: 2052 | 4-word phrases: 2174

PAGE INFO

Title	Try to keep the title under 60 characters (179 characters) LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	at week 16	11	0.54%
2	300 mg every	11	0.54%
3	adbry 300 mg	11	0.54%
4	every other week	10	0.49%
5	mg every other	9	0.44%
6	your healthcare provider	8	0.39%
7	ecztra 1 and	7	0.34%
8	treated with adbry	7	0.34%
9	with adbry 300	7	0.34%
10	with moderatetosevere atopic	6	0.29%
11	1 and 2	6	0.29%
12	approval of adbry	5	0.24%
13	patients treated with	5	0.24%
14	moderatetosevere atopic dermatitis	5	0.24%
15	adults with moderatetosevere	4	0.19%
16	and 2 respectively	4	0.19%
17	the il13 cytokine	4	0.19%
18	with or without	4	0.19%
19	adbry can be	4	0.19%
20	can be used	4	0.19%
21	the first and	4	0.19%
22	fda approval of	4	0.19%
23	first and only	4	0.19%
24	for adults with	3	0.15%
25	of patients who	3	0.15%
26	leo pharma as	3	0.15%
27	plus tcs achieved	3	0.15%
28	week plus tcs	3	0.15%
29	other week plus	3	0.15%
30	used with or	3	0.15%

#	Keyword	Frequency	Density
1	300 mg every other	9	0.41%
2	mg every other week	9	0.41%
3	adbry 300 mg every	9	0.41%
4	with adbry 300 mg	7	0.32%
5	treated with adbry 300	5	0.23%
6	ecztra 1 and 2	5	0.23%
7	patients treated with adbry	5	0.23%
8	adbry can be used	4	0.18%
9	fda approval of adbry	4	0.18%
10	1 and 2 respectively	4	0.18%
11	for the treatment of	3	0.14%
12	every other week achieved	3	0.14%
13	2 and ecztra 3	3	0.14%
14	responded at week 16	3	0.14%
15	adbry is the first	3	0.14%
16	with or without topical	3	0.14%
17	side effects of adbry?	3	0.14%
18	used with or without	3	0.14%
19	at week 16 for	3	0.14%
20	every other week plus	3	0.14%
21	other week plus tcs	3	0.14%
22	be used with or	3	0.14%
23	average worst daily pruritus	3	0.14%
24	weekly average worst daily	3	0.14%
25	with placebo plus tcs1	3	0.14%
26	at week 16 maintained	3	0.14%
27	week plus tcs achieved	3	0.14%
28	can be used with	3	0.14%
29	adults with moderatetosevere atopic	3	0.14%
30	side effects of adbry	3	0.14%
31	announces fda approval of	3	0.14%
32	fda approval of adbry™	3	0.14%
33	clear skin iga 01	3	0.14%
34	targeting il13 for adults	3	0.14%
35	il13 for adults with	3	0.14%
36	of leo pharma as	3	0.14%
37	the first and only	3	0.14%
38	placebo plus tcs1 at	2	0.09%
39	that specifically binds to	2	0.09%
40	dermatitis signs and symptoms134	2	0.09%

#	URL	Whois	Check
1	http://browsehappy.com/	Whois	browsehappy.com
2	https://www.leo-pharma.us/Files/Billeder/US%20Website%20Product%20PIs/AdbryPI.pdf	Whois	leo-pharma.us
3	http://www.LEO-Pharma.us	Whois	LEO-Pharma.us
4	http://www.isebox.com/terms-and-conditions	Whois	isebox.com
5	http://www.isebox.com/privacy	Whois	isebox.com
6	https://support.isebox.com/knowledgebase/topics/131149-8	Whois	isebox.com
7	https://isebox.com/terms-and-conditions	Whois	isebox.com
8	https://isebox.com/privacy	Whois	isebox.com